Neuromuscular Autoimmune Disease
Immunabs Inc. is active in clinical research for generalized myasthenia gravis and ocular myasthenia gravis, with attention to both AChR antibody-positive and AChR antibody-negative patient populations.
- Generalized myasthenia gravis
- Ocular myasthenia gravis
- AChR antibody-positive disease
- AChR antibody-negative disease
The sponsor’s research activity in this area centers on treatment options for autoimmune weakness affecting skeletal muscle function and eye movement.
Immune-Mediated Antibody Targeting
The funded research landscape includes therapeutic interest in autoantibody-associated neuromuscular disorders, reflecting a focus on disease mechanisms linked to acetylcholine receptor antibodies.
- Autoantibody-associated neuromuscular disease
- Acetylcholine receptor antibodies
- Immune-mediated muscle weakness
Clinical activity is directed toward therapies intended for patients whose symptoms arise from immune attack on neuromuscular signaling.
Therapeutic Development in Myasthenic Syndromes
Immunabs Inc. is pursuing clinical investigation in myasthenic syndromes with a therapeutic emphasis on both symptom control and functional improvement across generalized and ocular presentations.
- Myasthenic syndromes
- Symptom control
- Functional improvement
This area of interest spans disease manifestations that affect limb strength, bulbar function, and ocular motility.
Multinational Clinical Research
The sponsor’s trial activity extends across multiple countries and collaborating research sites, supporting clinical evaluation in a geographically diverse patient population within Asia and beyond.
- Multicenter clinical research
- International patient recruitment
- Cross-country trial access
Research operations are centered in Songpa, South Korea, with active study involvement in several regions.
